How much does the lung cancer drug brigatinib/brigatinib cost?

Brigatinib/Brigatinib (Brigatinib) is an important treatment drug for adults with non-small cell lung cancer (NSCLC). It is particularly suitable for patients who have not received ALK inhibitor treatment or have previously received crizotinib, an ALK inhibitor. But it is worth noting that brigatinib is mainly used to treat ALK-positive non-small cell lung cancer, which means that the patient's cancer cells have undergone specific genetic mutations, leading to abnormal production of ALK (anaplastic lymphoma kinase) protein.

ALK is a member of the receptor tyrosine kinase family, which plays a key role in cell growth and the formation of new blood vessels. In patients with ALK-positive non-small cell lung cancer, the abnormal form of ALK causes cancer cells to divide and proliferate uncontrollably. The core component of brigatinib can effectively block the activity of ALK, thereby inhibiting the growth and spread of cancer cells.

Currently, the original drug of brigatinib has been launched in the domestic market and has been included in the Class B medical insurance drug catalog. Common specifications on the market include 30mg 14 tablets in 2 boards, 90mg 7 tablets in 4 boards, 90mg 7 tablets and 180mg 7 tablets in 4 boards. However, the price of this drug is relatively high, and each box may cost up to about 10,000 yuan.

Fortunately, overseas markets also provide more affordable generic versions of brigatinib. There is almost no difference in the composition of these generic drugs from the brand-name drugs. For example, the generic brigatinib drug of 90mg*30 tablets produced by a Bangladeshi pharmaceutical factory sells for about 2,000 yuan per box (the price may fluctuate due to exchange rate changes). This provides a more economical option for patients who require long-term medication.